Do intra-articular steroid injections affect glycemic control in patients with diabetes?

Article Type
Changed
Tue, 05/03/2022 - 16:00
Display Headline
Do intra-articular steroid injections affect glycemic control in patients with diabetes?
EVIDENCE-BASED ANSWER

YES, BUT THE CLINICAL IMPORTANCE IS MINIMAL. A single intra-articular steroid injection into the knee produces acute hyperglycemia for 2 or 3 days in patients with diabetes who otherwise have good glucose control (strength of recommendation [SOR]: B, small cohort studies).

Intra-articular steroid injections into the shoulder may briefly raise postprandial (but not mean) glucose levels with larger and repeated doses (SOR: C, extrapolated from heterogenous and mixed cohort studies).

 

Evidence summary

Two prospective cohort studies evaluated the effect on glycemic control of a single glucocorticoid injection into the knee of patients with controlled type 2 diabetes (glycosylated hemoglobin A1c <7.0%). The first enrolled 9 patients with symptomatic osteoarthritis of the knee unresponsive to 3 months of nonsteroidal anti-inflammatory drugs (NSAIDs).1 All received a 50-mg injection of methylprednisolone acetate after maximal aspiration of any joint fluid. No changes were made to the diabetes care regimen, including medication, diet, or exercise prescriptions.

With self-monitoring 6 times a day during the week after the injection, 7 patients showed an increase over baseline blood glucose levels of more than 2 standard deviations; values typically rose above 300 mg/dL. Peak blood sugar elevation occurred 5 to 84 hours after injection; the hyperglycemic effect lasted for 2 or 3 days.

In a second cohort study, 6 patients received a knee injection of 1 mL Celestone Chronodose (3 mg betamethasone acetate and 3 mg betamethasone sodium phosphate, comparable in anti-inflammatory and glucocorticoid potency to 32 mg methylprednisolone acetate).2 Patients monitored their blood glucose 6 times a day for 1 week; investigators measured fructosamine levels (a measure of intermediate-term glucose control) at baseline and again 2 weeks after injection.

The injection produced hyperglycemia in all participants, with peak blood glucose levels ranging from 251 to 430 mg/dL and time to peak glucose usually less than 6 hours. Fructosamine levels didn’t change significantly.

No change in glucose after a single shoulder injection
Two studies evaluated the effect of a single shoulder injection. One prospective cohort study included 18 patients with diabetes (type not specified, mean A1c=7.6%).3 All had shoulder pain unresponsive to NSAIDs for more than a month, had not changed diabetes medications within the preceding 2 weeks, and had not had steroid therapy within the preceding 3 months.

All patients received a single injection containing 35 mg methylprednisolone acetate into the anterior glenohumeral joint. They monitored their blood glucose levels 6 times a day for 1 week and had a fructosamine level drawn before injection and 2 weeks afterward. The injection produced no significant change in mean blood glucose or fructosamine levels.

But repeated shoulder injections raise postprandial glucose
In contrast, another prospective cohort study followed 11 patients (8 with diabetes) who received 3 injections of 3.75 mg cortivazol (comparable to 50 mg methylprednisolone acetate) at 3-day intervals into 1 shoulder joint.4 Investigators checked fasting and postprandial glucose levels before the first injection and on post-treatment days 1, 7, and 21.

The shoulder injections elevated post-prandial glucose levels (from 170±60 mg/dL at baseline to 258±100 mg/dL on day 1 and 252±87 mg/dL on day 7; P<.05 for both comparisons). Mean fasting glucose levels didn’t change, however.

Recommendations

The American Academy of Orthopedic Surgeons treatment guidelines for osteoarthritis of the knee don’t discuss possible adverse effects from steroid injections.5 The American Diabetes Association makes no recommendations regarding steroid injections in patients with diabetes.

References

1. Habib GS, Bashir M, Jabbour A. Increased blood glucose levels following intra-articular injection of methylprednisolone acetate in patients with controlled diabetes and symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2008;67:1790-1791.

2. Habib G, Safia A. The effect of intra-articular injection of beta-methasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheumatol. 2009;28:85-87.

3. Habib GS, Abu-Ahmad R. Lack of effect of corticosteroid injection at the shoulder joint on blood glucose levels in diabetic patients. Clin Rheumatol. 2007;26:566-568.

4. Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine. 2007;74:472-476.

5. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthoplasty). Available at: www.aaos.org/research/guidelines/OAKguideline.pdf. Accessed July 2, 2009.

Article PDF
Author and Disclosure Information

Erin Kallock, MD
Jon O. Neher, MD
Valley Family Medicine Residency, Renton, Wash.

Sarah Safranek, MLIS
University of Washington, Health Services Library, Seattle

Issue
The Journal of Family Practice - 59(12)
Publications
Topics
Page Number
709-710
Legacy Keywords
Erin Kallock; intra-articular steroid injection; acute hyperglycemia; glucose levels; postprandial; self-monitoring
Sections
Author and Disclosure Information

Erin Kallock, MD
Jon O. Neher, MD
Valley Family Medicine Residency, Renton, Wash.

Sarah Safranek, MLIS
University of Washington, Health Services Library, Seattle

Author and Disclosure Information

Erin Kallock, MD
Jon O. Neher, MD
Valley Family Medicine Residency, Renton, Wash.

Sarah Safranek, MLIS
University of Washington, Health Services Library, Seattle

Article PDF
Article PDF
EVIDENCE-BASED ANSWER

YES, BUT THE CLINICAL IMPORTANCE IS MINIMAL. A single intra-articular steroid injection into the knee produces acute hyperglycemia for 2 or 3 days in patients with diabetes who otherwise have good glucose control (strength of recommendation [SOR]: B, small cohort studies).

Intra-articular steroid injections into the shoulder may briefly raise postprandial (but not mean) glucose levels with larger and repeated doses (SOR: C, extrapolated from heterogenous and mixed cohort studies).

 

Evidence summary

Two prospective cohort studies evaluated the effect on glycemic control of a single glucocorticoid injection into the knee of patients with controlled type 2 diabetes (glycosylated hemoglobin A1c <7.0%). The first enrolled 9 patients with symptomatic osteoarthritis of the knee unresponsive to 3 months of nonsteroidal anti-inflammatory drugs (NSAIDs).1 All received a 50-mg injection of methylprednisolone acetate after maximal aspiration of any joint fluid. No changes were made to the diabetes care regimen, including medication, diet, or exercise prescriptions.

With self-monitoring 6 times a day during the week after the injection, 7 patients showed an increase over baseline blood glucose levels of more than 2 standard deviations; values typically rose above 300 mg/dL. Peak blood sugar elevation occurred 5 to 84 hours after injection; the hyperglycemic effect lasted for 2 or 3 days.

In a second cohort study, 6 patients received a knee injection of 1 mL Celestone Chronodose (3 mg betamethasone acetate and 3 mg betamethasone sodium phosphate, comparable in anti-inflammatory and glucocorticoid potency to 32 mg methylprednisolone acetate).2 Patients monitored their blood glucose 6 times a day for 1 week; investigators measured fructosamine levels (a measure of intermediate-term glucose control) at baseline and again 2 weeks after injection.

The injection produced hyperglycemia in all participants, with peak blood glucose levels ranging from 251 to 430 mg/dL and time to peak glucose usually less than 6 hours. Fructosamine levels didn’t change significantly.

No change in glucose after a single shoulder injection
Two studies evaluated the effect of a single shoulder injection. One prospective cohort study included 18 patients with diabetes (type not specified, mean A1c=7.6%).3 All had shoulder pain unresponsive to NSAIDs for more than a month, had not changed diabetes medications within the preceding 2 weeks, and had not had steroid therapy within the preceding 3 months.

All patients received a single injection containing 35 mg methylprednisolone acetate into the anterior glenohumeral joint. They monitored their blood glucose levels 6 times a day for 1 week and had a fructosamine level drawn before injection and 2 weeks afterward. The injection produced no significant change in mean blood glucose or fructosamine levels.

But repeated shoulder injections raise postprandial glucose
In contrast, another prospective cohort study followed 11 patients (8 with diabetes) who received 3 injections of 3.75 mg cortivazol (comparable to 50 mg methylprednisolone acetate) at 3-day intervals into 1 shoulder joint.4 Investigators checked fasting and postprandial glucose levels before the first injection and on post-treatment days 1, 7, and 21.

The shoulder injections elevated post-prandial glucose levels (from 170±60 mg/dL at baseline to 258±100 mg/dL on day 1 and 252±87 mg/dL on day 7; P<.05 for both comparisons). Mean fasting glucose levels didn’t change, however.

Recommendations

The American Academy of Orthopedic Surgeons treatment guidelines for osteoarthritis of the knee don’t discuss possible adverse effects from steroid injections.5 The American Diabetes Association makes no recommendations regarding steroid injections in patients with diabetes.

EVIDENCE-BASED ANSWER

YES, BUT THE CLINICAL IMPORTANCE IS MINIMAL. A single intra-articular steroid injection into the knee produces acute hyperglycemia for 2 or 3 days in patients with diabetes who otherwise have good glucose control (strength of recommendation [SOR]: B, small cohort studies).

Intra-articular steroid injections into the shoulder may briefly raise postprandial (but not mean) glucose levels with larger and repeated doses (SOR: C, extrapolated from heterogenous and mixed cohort studies).

 

Evidence summary

Two prospective cohort studies evaluated the effect on glycemic control of a single glucocorticoid injection into the knee of patients with controlled type 2 diabetes (glycosylated hemoglobin A1c <7.0%). The first enrolled 9 patients with symptomatic osteoarthritis of the knee unresponsive to 3 months of nonsteroidal anti-inflammatory drugs (NSAIDs).1 All received a 50-mg injection of methylprednisolone acetate after maximal aspiration of any joint fluid. No changes were made to the diabetes care regimen, including medication, diet, or exercise prescriptions.

With self-monitoring 6 times a day during the week after the injection, 7 patients showed an increase over baseline blood glucose levels of more than 2 standard deviations; values typically rose above 300 mg/dL. Peak blood sugar elevation occurred 5 to 84 hours after injection; the hyperglycemic effect lasted for 2 or 3 days.

In a second cohort study, 6 patients received a knee injection of 1 mL Celestone Chronodose (3 mg betamethasone acetate and 3 mg betamethasone sodium phosphate, comparable in anti-inflammatory and glucocorticoid potency to 32 mg methylprednisolone acetate).2 Patients monitored their blood glucose 6 times a day for 1 week; investigators measured fructosamine levels (a measure of intermediate-term glucose control) at baseline and again 2 weeks after injection.

The injection produced hyperglycemia in all participants, with peak blood glucose levels ranging from 251 to 430 mg/dL and time to peak glucose usually less than 6 hours. Fructosamine levels didn’t change significantly.

No change in glucose after a single shoulder injection
Two studies evaluated the effect of a single shoulder injection. One prospective cohort study included 18 patients with diabetes (type not specified, mean A1c=7.6%).3 All had shoulder pain unresponsive to NSAIDs for more than a month, had not changed diabetes medications within the preceding 2 weeks, and had not had steroid therapy within the preceding 3 months.

All patients received a single injection containing 35 mg methylprednisolone acetate into the anterior glenohumeral joint. They monitored their blood glucose levels 6 times a day for 1 week and had a fructosamine level drawn before injection and 2 weeks afterward. The injection produced no significant change in mean blood glucose or fructosamine levels.

But repeated shoulder injections raise postprandial glucose
In contrast, another prospective cohort study followed 11 patients (8 with diabetes) who received 3 injections of 3.75 mg cortivazol (comparable to 50 mg methylprednisolone acetate) at 3-day intervals into 1 shoulder joint.4 Investigators checked fasting and postprandial glucose levels before the first injection and on post-treatment days 1, 7, and 21.

The shoulder injections elevated post-prandial glucose levels (from 170±60 mg/dL at baseline to 258±100 mg/dL on day 1 and 252±87 mg/dL on day 7; P<.05 for both comparisons). Mean fasting glucose levels didn’t change, however.

Recommendations

The American Academy of Orthopedic Surgeons treatment guidelines for osteoarthritis of the knee don’t discuss possible adverse effects from steroid injections.5 The American Diabetes Association makes no recommendations regarding steroid injections in patients with diabetes.

References

1. Habib GS, Bashir M, Jabbour A. Increased blood glucose levels following intra-articular injection of methylprednisolone acetate in patients with controlled diabetes and symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2008;67:1790-1791.

2. Habib G, Safia A. The effect of intra-articular injection of beta-methasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheumatol. 2009;28:85-87.

3. Habib GS, Abu-Ahmad R. Lack of effect of corticosteroid injection at the shoulder joint on blood glucose levels in diabetic patients. Clin Rheumatol. 2007;26:566-568.

4. Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine. 2007;74:472-476.

5. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthoplasty). Available at: www.aaos.org/research/guidelines/OAKguideline.pdf. Accessed July 2, 2009.

References

1. Habib GS, Bashir M, Jabbour A. Increased blood glucose levels following intra-articular injection of methylprednisolone acetate in patients with controlled diabetes and symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2008;67:1790-1791.

2. Habib G, Safia A. The effect of intra-articular injection of beta-methasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheumatol. 2009;28:85-87.

3. Habib GS, Abu-Ahmad R. Lack of effect of corticosteroid injection at the shoulder joint on blood glucose levels in diabetic patients. Clin Rheumatol. 2007;26:566-568.

4. Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine. 2007;74:472-476.

5. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthoplasty). Available at: www.aaos.org/research/guidelines/OAKguideline.pdf. Accessed July 2, 2009.

Issue
The Journal of Family Practice - 59(12)
Issue
The Journal of Family Practice - 59(12)
Page Number
709-710
Page Number
709-710
Publications
Publications
Topics
Article Type
Display Headline
Do intra-articular steroid injections affect glycemic control in patients with diabetes?
Display Headline
Do intra-articular steroid injections affect glycemic control in patients with diabetes?
Legacy Keywords
Erin Kallock; intra-articular steroid injection; acute hyperglycemia; glucose levels; postprandial; self-monitoring
Legacy Keywords
Erin Kallock; intra-articular steroid injection; acute hyperglycemia; glucose levels; postprandial; self-monitoring
Sections
PURLs Copyright

Evidence-based answers from the Family Physicians Inquiries Network

Disallow All Ads
Article PDF Media